Amundi
LGND icon

Amundi’s Ligand Pharmaceuticals LGND Stock Holding History

Amundi’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$710K Buy
3,555
+522
+17% +$103K ﹤0.01% 1407
2025
Q4 		$573K Sell
3,033
-323
-10% -$62.1K ﹤0.01% 1424
2025
Q3 		$613K Buy
3,356
+229
+7% +$34K ﹤0.01% 1274
2025
Q2 		$355K Sell
3,127
-4,500
-59% -$481K ﹤0.01% 1458
2025
Q1 		$786K Sell
7,627
-1,921
-20% -$217K ﹤0.01% 1387
2024
Q4 		$1.06M Buy
9,548
+6,332
+197% +$716K ﹤0.01% 1392
2024
Q3 		$331K Buy
3,216
+582
+22% +$58.6K ﹤0.01% 1527
2024
Q2 		$218K Sell
2,634
-240
-8% -$19.1K ﹤0.01% 1564
2024
Q1 		$208K Buy
2,874
+709
+33% +$52.3K ﹤0.01% 1628
2023
Q4 		$159K Buy
2,165
+141
+7% +$8.32K ﹤0.01% 1684
2023
Q3 		$111K Hold
2,024
– – ﹤0.01% 1735
2023
Q2 		$147K Sell
2,024
-163
-7% -$12.2K ﹤0.01% 1682
2023
Q1 		$156K Buy
+2,187
New +$155K ﹤0.01% 1636

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Amundi's LGND Position: Q1 2026 in Review

Amundi increased its Ligand Pharmaceuticals (LGND) stake by 17% in Q1 2026, buying an estimated $103K and bringing the position to 3,555 shares worth $710K. The position accounts for ﹤0.01% of the portfolio, ranked #1407.

Amundi first reported a position in LGND in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.06M in Q4 2024. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Amundi held 3,555 shares of Ligand Pharmaceuticals worth $710K as of Q1 2026.
  • Amundi bought 522 Ligand Pharmaceuticals shares in Q1 2026, an estimated $103K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1407 holding.
  • Amundi first reported a position in Ligand Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Amundi's Ligand Pharmaceuticals position peaked at $1.06M in Q4 2024.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.